Bladder Disease
17
4
5
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.9%
1 terminated out of 17 trials
90.0%
+3.5% vs benchmark
6%
1 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (17)
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
ECHO-012 Kosmos Bladder Clinical Validation Study
Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Trimodality Treatment in Bladder Cancer
Osteoporosis, Trabecular Bone Score and Fracture Risk Assessment in Male Patients After Radical Cystectomy
Different Injection Site Maps & Intravesical Botulinum Toxin
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy
A Trial of a Modified Cystoscopy Method to Reduce Pain Perception
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
Perioperative Multimodal Care for Cystectomy Frail Patient
Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure